GSK To Overhaul Emerging Markets Model
Executive Summary
Although GSK has seen some difficult times in emerging markets in recent years, CEO Emma Walmsley says it continues to be a key region for the company and plans significant changes to its business there to improve competitiveness and roll out more innovations.
You may also be interested in...
Portfolio Streamlining At GSK India But Long Term Commitment Intact
GlaxoSmithKline has initiated portfolio rationalization measures in India as the British multinational reshapes its emerging markets business model with an eye on driving sustained profitable growth. But the company has also underscored its long-term commitment to the country, where it expects to build on its “strong heritage” and expand patient access.
GSK Closes China Neuroscience Center In Latest R&D Reorganization
The axe comes sooner but was not unexpected, given past controversy and a fresh direction under the leadership of GSK's new CEO Emma Walmsley who once spent years in Shanghai, where the company’s China R&D center is located.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.